(Reuters) -Merck has signed a licensing agreement for a heart disease drug with Jiangsu Hengrui Pharmaceuticals worth up to $2 billion, the latest in a series of deals U.S. drugmakers have ...

Merck & Co – known as MSD outside the US and Canada – has said it will be gaining exclusive global rights to Jiangsu Hengrui Pharmaceuticals’ investigational cardiovascular disease (CVD) drug in a ...

The deal will give the U.S. drugmaker access to an experimental heart disease drug. “The companies ... Hengrui Pharma has granted Merck exclusive rights to develop, manufacture and commercialize ...

Per the terms of the deal, Merck will acquire the global rights (excluding Greater China ... are a significant risk factor for cardiovascular disease like heart attack and stroke.

Under the latest deal, Merck gets exclusive rights to develop, manufacture and sell Jiangsu Hengrui Pharmaceuticals’ experimental oral heart disease drug, HRS-5346. Hengrui Pharma will ...

With the CSF-1R inhibitor space heating up, Merck KGaA ... license to the drug. The German pharma originally paid $70 million for the greater China commercialization rights back in 2023, while ...

Under the agreement, Hengrui Pharma has granted Merck exclusive rights to develop ... risk factor for atherosclerotic cardiovascular disease, affecting as many as one in five adults globally ...

Merck will partner with Chinese biotech Abbisko Therapeutics to market and sell the bone-tumor treatment pimicotinib globally, expanding its commercialization rights for the drug beyond Asia.